Abstract Number: 2594 • 2018 ACR/ARHP Annual Meeting
Median Time to Pain Improvement in Patients with Psoriatic Arthritis Treated with Tofacitinib
Background/Purpose: Pain is a core domain of psoriatic arthritis (PsA).1 Rapid, sustained pain reduction is a priority for patients (pts) and physicians when choosing treatment.…Abstract Number: 2652 • 2018 ACR/ARHP Annual Meeting
Engaging the Cholinergic Anti-Inflammatory Pathway By Stimulating the Vagus Nerve Reduces Pain and Fatigue in Patients with SLE
Background/Purpose: Musculoskeletal (MS) pain is a common symptom of patients with Systemic Lupus Erythematosus (SLE) affecting up to 95% of patients and contributing to…Abstract Number: 2868 • 2018 ACR/ARHP Annual Meeting
Tender Joint Count May Not Reflect Inflammatory Activity in Established Rheumatoid Arthritis Patients; Results from a Longitudinal Study of Tocilizumab
Background/Purpose: Tender joints may be caused by non-inflammatory pathologies but are still included in composite scores like CDAI. The present objective was to explore the…Abstract Number: 405 • 2018 ACR/ARHP Annual Meeting
Feasibility of Enabling Self-Management and Coping with Arthritic Pain Using Exercise (ESCAPE-Pain) Programme for Knee Osteoarthritis in Malaysia
Background/Purpose: In Malaysia around one in ten older people are diagnosed with osteoarthritis (OA), with the knee being one of the most commonly affected areas.…Abstract Number: 447 • 2018 ACR/ARHP Annual Meeting
Discriminating between Central & Peripheral Pain Sensitization Using a Slowly Repeated Evoked Pain Protocol
Background/Purpose: In a prior study, the response of pain sensitization by fibromyalgia (FM) patients to a protocol of Slowly Repeated Evoked Pain (SREP)* was strongly…Abstract Number: 450 • 2018 ACR/ARHP Annual Meeting
Injection Site Reaction Associated with Subcutaneous Biologic Agents and Methotrexate. Analysis from the Rhumadata® Clinical Database and Registry
Background/Purpose: Injection Site Reaction (ISRs) are associated with the subcutaneous (SC) route of administration of all biologic agents, and 3% to 15% of patients reports…Abstract Number: 933 • 2018 ACR/ARHP Annual Meeting
Inflammation in the Hippocampus Affects Insulin-like Growth Factor-1 Receptor Signaling and Contributes to Neurological Sequelae in Rheumatoid Arthritis
Background/Purpose: The central nervous system is not the primary target in rheumatoid arthritis (RA). However, neuropsychiatric symptoms including pain, depression and anxiety are common and…Abstract Number: 1159 • 2018 ACR/ARHP Annual Meeting
Fat Mass Is Associated with Musculoskeletal Pain in Women : A Three-Year Longitudinal Study
Background/Purpose: Increase in fat mass is correlated with musculoskeletal pain. The aim of this study was to examine the relationship between fat mass and the…Abstract Number: 1392 • 2018 ACR/ARHP Annual Meeting
Decreased Injection Site Pain Associated with New Etanercept Formulation in Patients with Rheumatoid Arthritis or Psoriatic Arthritis
Background/Purpose: Injection site pain (ISP) is a component of the patient experience with injectable drugs. A new formulation of etanercept was developed to reduce ISP.…Abstract Number: 1558 • 2018 ACR/ARHP Annual Meeting
Intravenous Immunoglobulin Efficacy for Primary Sjögren’s Syndrome Associated Small Fiber Neuropathy
Background/Purpose: To analyze the efficacy and tolerance of intravenous immunoglobulin (IVIG) therapy in 11 patients with primary Sjögren's syndrome (pSS)-associated small-fiber neuropathy (SFN).Methods: Retrospective, single-center…Abstract Number: 1644 • 2018 ACR/ARHP Annual Meeting
Improvement in Morning Stiffness in Subjects with Psa Is Associated with Improvements in Pain, Physical Function, and Patient Global Response to Treatment
Background/Purpose: Stiffness is an important component of inflammatory arthritis and plays a role in PsA flare. Patients with inflammatory arthritis report difficulty with activities, “slowing…Abstract Number: 1918 • 2018 ACR/ARHP Annual Meeting
Defining Pain That Does Not Interfere with Activities Among Rheumatoid Arthritis (RA) Patients
Background/Purpose: RA patients differ in the degree to which pain interferes with function. To improve function, an understanding of this diversity is needed. Our objectives…Abstract Number: 1922 • 2018 ACR/ARHP Annual Meeting
Characterization of the Pharmacology and Pharmacokinetics of Cntx-4975, a High-Purity, Synthetic Trans-Capsaicin in Clinical Development for the Treatment of Moderate to Severe OA Knee Pain
Background/Purpose: CNTX-4975, a highly purified, synthetic trans-capsaicin and long-acting, non-opioid analgesic in phase 3 trials for moderate to severe OA knee pain, has demonstrated safety…Abstract Number: 2531 • 2018 ACR/ARHP Annual Meeting
Assessment of Pain Relief with Baricitinib By Treatment History in Patients with Refractory Rheumatoid Arthritis
Background/Purpose: Baricitinib (BARI) 2 mg and 4 mg once daily demonstrated significant clinical improvements compared to placebo in the phase 3 study of RA patients…Abstract Number: 2563 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of a Potent and Highly Selective Oral Tyrosine Kinase 2 Inhibitor, BMS-986165, in Patients with Moderate-to-Severe Plaque Psoriasis: A Phase II, Randomized, Placebo-Controlled Trial
Background/Purpose: BMS-986165, a potent and highly selective oral tyrosine kinase 2 inhibitor, inhibits signal transducer and activator of transcription (STAT)-dependent signalling pathways of interleukin-23 and…
- 1
- 2
- 3
- …
- 8
- Next Page »